WilliamDamskyMD

Dermatology • New Haven, CT

Dermatopathology

Assistant Professor of Dermatology and Pathology

Join to view full profile

Dr. Damsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Damsky's full profile

Already have an account?

Office
428 Columbus Ave
New Haven, CT 06519
Phone+1 203-503-3000

Fax+1 203-785-7637

Education & Training

Yale-New Haven Medical CenterResidency, Internal Medicine, 2013 - 2014
University of Vermont College of MedicineClass of 2013

Certifications & Licensure

FL State Medical License 2022 - Present
CT State Medical License 2017 - 2025
American Board of Dermatology Dermatology
American Board of Dermatology Dermatopathology

Clinical Trials

Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare Start of enrollment: 2019 Apr 11
Completed
Phase 1
Janus Kinase Inhibition in Sarcoidosis Start of enrollment: 2023 Jun 01
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Janus Kinase Inhibition in Granuloma Annulare Start of enrollment: 2023 Oct 27
Active, not recruiting
Phase 2
Roles: Sponsor-Investigator, Principal Investigator, Contact

Publications & Presentations

PubMed

Granuloma Annulare Exhibits Mixed Immune and Macrophage Polarization Profiles with Spatial Transcriptomics.
Chitrasen Mohanty, Chandra K Singh, Joseph A Daccache, William Damsky, Christina Kendziorski
The Journal of Investigative Dermatology. 2025-01-01
Spatial transcriptomics reveals organized and distinct immune activation in cutaneous granulomatous disorders.
Joseph Daccache, Eunsuh Park, Muhammad Junejo, Mariam Abdelghaffar, Erica Hwang
The Journal of Allergy and Clinical Immunology. 2024-11-01
Mapping intratumoral myeloid-T cell interactomes at single-cell resolution reveals targets for overcoming checkpoint inhibitor resistance.
Kate Bridges, Gabriela A Pizzurro, Alev Baysoy, Janani P Baskaran, Ziyan Xu
Biorxiv. 2024-10-31

Lectures

JAK Inhibitors: A New Frontier in Dermatology
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/1/2019

Press Mentions

TNF or JAK: Which Target Is Key to Success in Tough-to-Treat Skin Disease?November 11th, 2021
Dramatic Responses in Cutaneous Sarcoidosis with JAK InhibitorNovember 7th, 2021
Yale Cancer Center Study Shows New Strategy to Boost Immune System to Fight MelanomaOctober 19th, 2021
Join now to see all